Application of electronic portal imaging device in dose verification of intensity-modulated radiotherapy(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2018年第7期
- Page:
- 776-780
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Application of electronic portal imaging device in dose verification of intensity-modulated radiotherapy
- Author(s):
- LIU Shupeng1; CHEN Weisi2; HOU Mingyang3; CHENG Xiyuan4; CHEN Along5
- 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2. Center for Radiation Physics and Treatment, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, China; 3. Department of Equipment, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 4. S.M.U Medical Equipment Test Co., Ltd., Southern Medical University, Guangzhou 510515, China; 5. Department of Radiation Oncology, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China
- Keywords:
- ; Keywords: intensity-modulated radiotherapy; volume modulated arc therapy; electronic portal imaging device; Rapidose; gamma passing rate; dose verification
- PACS:
- R815
- DOI:
- DOI:10.3969/j.issn.1005-202X.2018.07.007
- Abstract:
- Abstract: Objective To explore the practicability of dose verification of intensity-modulated radiotherapy (IMRT) and volume modulated arc therapy (VMAT) on Elekta (Synergy) linear accelerator via Rapidose dose analysis software combined with electronic portal imaging device (EPID). Methods Eleven IMRT plans and 6 VMAT plans were randomly selected. The gamma passing rates of these plans were measured with different validation devices (EPID, MatriXX, ArcCHECK and CC13 ionization chamber) and compared under different gamma standards (5 mm, 3%; 3 mm, 3%; 2 mm, 2%). Results The gamma passing rates measured with EPID were (99.86±0.13)%, (99.06±0.45)%, (92.17±4.89)% for IMRT plans, and (99.77±0.21)%, (97.75±1.20)%, (85.91±6.82)% for VMAT plans. The gamma passing rates measured with MatriXX were (99.47±0.95)%, (98.60±1.10)%, (90.56±5.07)% for IMRT plans, and (99.51±0.40)%, (97.24±1.05)%, (87.21±4.17)% for VMAT plans. The gamma passing rates measured with ArcCHECK were (99.34±0.46)%, (98.21±1.31)%, (89.89±1.70)% for IMRT plans, and (99.93±0.08)%, (98.66±0.35)% and (96.03±2.90)% for VMAT plans. The dose deviation of CC13 ionization chamber was (1.10±1.84)% and (0.59±1.31)% for IMRT plans and VMAT plans, respectively. The paired-t test comparison results revealed that all measurements of the 3 devices met the clinical requirements. Conclusion EPID can be combined with Rapidose dose analysis software to meet the clinical dose verification requirements of IMRT plans and VMAT plans.
Last Update: 2018-07-24